Recall: D-0471-2026
Class II - Potentially Harmful
Class IIClassification
2026-03-06Initiated
OngoingStatus
PAYLESS COMPOUNDERS, LLCFirm
Product
Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR
Reason
Lack of Assurance of Sterility
Distribution
OR
Source: FDA drug enforcement report via openFDA (Voluntary: Firm initiated). If you take this product, talk to your pharmacist or doctor before stopping it.